Article
Changes in the concentration of EGFR-mutated plasma DNA in the first hours of targeted therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer.
International journal of clinical oncology - 1 May 2022
Moiseyenko Fedor V, Kuligina Ekaterina S, Zhabina Albina S, Belukhin Sergey A, Laidus Tatiana A, Martianov Aleksandr S, Zagorodnev Kirill A, Sokolova Tatyana N, Chuinyshena Svetlana A, Kholmatov Maxim M, Artemieva Elizaveta V, Stepanova Ekaterina O, Shuginova Tatiana N, Volkov Nikita M, Yanus Grigoriy A, Imyanitov Evgeny N
Abstract excerpt
PURPOSE: This study aimed to analyze changes in the plasma concentration of EGFR-mutated circulating tumor DNA (ctDNA) occurring immediately after the start of therapy with EGFR tyrosine kinase inhibitors (TKIs). METHODS: Serial plasma samples were collected from 30 patients with EGFR-driven non-small cell lung cancer before intake of the first tablet and at 0.5, 1, 2, 3, 6, 12, 24, 36 and 48 h after the start of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.